Zevra Therapeutics(ZVRA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights FDA advisory committee voted favorably that the data support arimoclomol as effective treatment for patients with NPC; PDUFA date of September 21, 2024 Pro-forma June 30, 2024, cash, cash equivalents, investments and net proceeds from underwritten public offering total $113.8 million following the closing on August 12, 2024 Conference call scheduled for today, August 13, 2024, at 4:30 p.m. ET Celebration, ...